[en] In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX(R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX(R)-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX(R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate.
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Kaufman, J. M.
Goemaere, S.
Devogelaer, J. P.
Benhamou, C. L.
Felsenberg, D.
Diaz-Curiel, M.
Brandi, M. L.
Badurski, J.
Wark, J.
Balogh, A.
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
DD Mellstrom OH Sorensen S Goemaere, et al. 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 462 8 15455188 10.1007/s00223-004-0286-7 1:STN:280:DC%2BD2M%2FisFSktA%3D%3D (Pubitemid 40174503)
DM Black AV Schwartz KE Ensrud, et al. 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 38 17190893 10.1001/jama.296.24.2927 1:CAS:528:DC%2BD2sXnvVGh (Pubitemid 46021497)
Black DM, Reid I, Cauley J et al. (2010) The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Abstract 1070. J Bone Miner Res 25 (suppl 1):
S Martino JA Cauley E Barrett-Connor, et al. 2004 Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 1751 61 15572757 10.1093/jnci/djh319 1:CAS:528:DC%2BD2cXhtVCrsrjM (Pubitemid 39654569)
ES Siris ST Harris R Eastell, et al. 2005 Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study J Bone Miner Res 20 1514 24 16059623 10.1359/JBMR.050509 1:CAS:528:DC%2BD2MXhtVOltrrP (Pubitemid 41243540)
S Papapoulos Z Man D Mellstrom, et al. 2011 Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension. OC24 Osteoporos Int 22 suppl 1 S107
PD Miller RB Wagman M Peacock, et al. 2011 Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial J Clin Endocrinol Metab 96 394 402 21159841 10.1210/jc.2010-1805 1:CAS:528:DC%2BC3MXisVOms7Y%3D
PJ Marie 2007 Strontium ranelate: new insights into its dual mode of action Bone 40 S5 S8 10.1016/j.bone.2007.02.003 1:CAS:528:DC%2BD2sXktF2nsL8%3D (Pubitemid 46562594)
PJ Meunier C Roux E Seeman, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 68 14749454 10.1056/NEJMoa022436 1:CAS:528: DC%2BD2cXos1Snsw%3D%3D (Pubitemid 38133766)
JY Reginster E Seeman MC De Vernejoul, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 22 15728210 10.1210/jc.2004-1774 1:CAS:528: DC%2BD2MXkt1Wgt78%3D (Pubitemid 40686329)
C Roux J-Y Reginster J Fechtenbaum, et al. 2006 Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536 42 16598373 10.1359/jbmr.060101 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D
JY Reginster D Felsenberg S Boonen, et al. 2008 Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial Arthritis Rheum 58 1687 95 18512789 10.1002/art.23461 1:CAS:528:DC%2BD1cXotVOntrg%3D (Pubitemid 351847521)
JY Reginster O Bruyere A Sawicki, et al. 2009 Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years Bone 45 1059 64 19679207 10.1016/j.bone.2009.08.004 1:CAS:528:DC%2BD1MXhtlGit7bE
HK Genant CY Wu C Van Kuijk, et al. 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 48 8237484 10.1002/jbmr.5650080915 1:STN:280:DyaK2c%2FlsFyhuw%3D%3D (Pubitemid 23261108)
DO Slosman DM Provvedini PJ Meunier, et al. 1999 The use of different dual X-ray absorptiometry brands in a multicenter clinical trial Consequences and limits. J Clin Densitom 2 37 44 10.1385/JCD:2:1:37
JA Kanis O Johnell A Oden, et al. 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 97 18292978 10.1007/s00198-007-0543-5 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D
WHO Collaborating Centre for Metabolic Bone Diseases (2008) FRAX WHO fracture risk assessment tool. Available at: http://www.shef.ac.uk/FRAX/. Accessed 27 April 2011
K Briot F Tremollieres T Thomas, et al. 2007 How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 74 24 31 17223374 10.1016/j.jbspin.2006.05.011
HG Bone D Hosking JP Devogelaer, et al. 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 99 15028823 10.1056/NEJMoa030897 1:CAS:528:DC%2BD2cXit12rsLc%3D (Pubitemid 38339363)
Kanis JA, Johansson H, Oden A et al. (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int In press
McCloskey E, Johansson H, Oden A et al. (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Abstract OC15. Osteoporos Int 22 (suppl 1):S103
EV McCloskey H Johansson A Oden, et al. 2009 Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study Osteoporos Int 20 811 7 19002369 10.1007/s00198-008-0786-9 1:CAS:528:DC%2BD1MXjvFaqt78%3D
SR Cummings DM Black DE Thompson, et al. 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077 82 9875874 10.1001/jama.280.24.2077 1:CAS:528:DyaK1MXjsVWruw%3D%3D (Pubitemid 29014065)
E Vittinghoff CE McCulloch C Woo, et al. 2010 Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins Stat Med 29 1127 36 20209478
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.